CD274 and melanoma: In the clinical setting, another retrospective cohort study at our institution demonstrated that patients with melanoma receiving H1-specific antihistamines while also receiving anti–PD-1/PD-L1 ICIs had a markedly lower mortality rate than age-, sex-, and stage-matched controls not receiving these agents.